Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice

Biochemical and Biophysical Research Communications

Volumn 432, Issue 1, 2013, Pages 73-79

  Lee, Woojung ^a   Ham, Jungyeob ^a   Kwon, Hak Cheol ^a   Kim, Yong Kee ^b   Kim, Su Nam ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

Amorphastilbol; Anti diabetic; PPAR agonist

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; AMORPHASTILBOL; ANTIDIABETIC AGENT; GLUCOSE; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE RESPONSE; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; IN VITRO STUDY; LIPID METABOLISM; LIVER METABOLISM; MALE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD GLUCOSE; CANNABINOIDS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; LIVER; MALE; MICE; MICE, INBRED C57BL; OXIDATION-REDUCTION; PPAR ALPHA; PPAR GAMMA;

ANIMALIA; MUS;

EID: 84875370759     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.083     Document Type: Article

References (30)

1. Rathmann W., Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:2568-2569.
2. Kopelman P.G. Obesity as a medical problem. Nature 2000, 404:635-643.
3. Bajaj M., Defronzo R.A. Metabolic and molecular basis of insulin resistance. J. Nucl. Cardiol. 2003, 10:311-323.
4. Pendergrass M., Bertoldo A., Bonadonna R., Nucci G., Mandarino L., Cobelli C., Defronzo R.A. Muscle glucose transport and phosphorylation in type 2 diabetic, obese nondiabetic, and genetically predisposed individuals. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E92-100.
5. Bays H., Mandarino L., DeFronzo R.A. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 2004, 89:463-478.
6. Carpentier A., Mittelman S.D., Bergman R.N., Giacca A., Lewis G.F. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000, 49:399-408.
7. Kashyap S., Belfort R., Gastaldelli A., Pratipanawatr T., Berria R., Pratipanawatr W., Bajaj M., Mandarino L., DeFronzo R., Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003, 52:2461-2474.
8. Boden G., Chen X., Kolaczynski J.W., Polansky M. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects. J. Clin. Invest. 1997, 100:1107-1113.
9. Ferrannini E., Barrett E.J., Bevilacqua S., DeFronzo R.A. Effect of fatty acids on glucose production and utilization in man. J. Clin. Invest. 1983, 72:1737-1747.
10. Mokdad A.H., Ford E.S., Bowman B.A., Dietz W.H., Vinicor F., Bales V.S., Marks J.S. Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 2001, 289(2003):76-79.
11. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W. International Union of Pharmacology. LXI Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
12. Lee C.H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
13. Vidal-Puig A.J., Considine R.V., Jimenez-Linan M., Werman A., Pories W.J., Caro J.F., Flier J.S. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 1997, 99:2416-2422.
14. Dubois M., Pattou F., Kerr-Conte J., Gmyr V., Vandewalle B., Desreumaux P., Auwerx J., Schoonjans K., Lefebvre J. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000, 43:1165-1169.
15. Lehrke M., Lazar M.A. The many faces of PPARgamma. Cell 2005, 123:993-999.
16. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10:355-361.
17. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. 2003, 115(Suppl. 8A):42S-48S.
18. Bunger M., Hooiveld G.J., Kersten S., Muller M. Exploration of PPAR functions by microarray technology a paradigm for nutrigenomics. Biochim. Biophys. Acta 2007, 1771:1046-1064.
19. Bajaj M., Suraamornkul S., Hardies L.J., Glass L., Musi N., DeFronzo R.A. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007, 50:1723-1731.
20. Pickavance L.C., Brand C.L., Wassermann K., Wilding J.P. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br. J. Pharmacol. 2005, 144:308-316.
21. Reifel-Miller A., Otto K., Hawkins E., Barr R., Bensch W.R., Bull C., Dana S., Klausing K., Martin J.A., Rafaeloff-Phail R., Rafizadeh-Montrose C., Rhodes G., Robey R., Rojo I., Rungta D., Snyder D., Wilbur K., Zhang T., Zink R., Warshawsky A., Brozinick J.T. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol. Endocrinol. 2005, 19:1593-1605.
22. Mittra S., Sangle G., Tandon R., Sharma S., Roy S., Khanna V., Gupta A., Sattigeri J., Sharma L., Priyadarsiny P., Khattar S.K., Bora R.S., Saini K.S., Bansal V.S. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice. adipogenesis/or oedema?. Br. J. Pharmacol. 2007, 150:480-487.
23. Adeghate E., Adem A., Hasan M.Y., Tekes K., Kalasz H. Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med. Chem. J. 2011, 5:93-98.
24. Kim T., Lee W., Jeong K.H., Song J.H., Park S.H., Choi P., Kim S.N., Lee S., Ham J. Total synthesis and dual PPARalpha/gamma agonist effects of amorphastilbol and its synthetic derivatives. Bioorg. Med. Chem. Lett. 2012, 22:4122-4126.
25. Kim S.N., Choi H.Y., Lee W., Park G.M., Shin W.S., Kim Y.K. Sargaquinoic acid and sargahydroquinoic acid from Sargassum yezoense stimulate adipocyte differentiation through PPARalpha/gamma activation in 3T3-L1 cells. FEBS Lett. 2008, 582:3465-3472.
26. Matsuda J., Hosoda K., Itoh H., Son C., Doi K., Hanaoka I., Inoue G., Nishimura H., Yoshimasa Y., Yamori Y., Odaka H., Nakao K. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in wistar fatty rats and in cultured adipocytes. Diabetes 1998, 47:1809-1814.
27. Emilsson V., O'Dowd J., Wang S., Liu Y.L., Sennitt M., Heyman R., Cawthorne M.A. The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. Metabolism 2000, 49:1610-1615.
28. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
29. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
30. Holden P.R., Tugwood J.D. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol. 1999, 22:1-8.